CONTAINER RESIDUE AFTER THE ADMINISTRATION OF AQUEOUS ACTIVATED-CHARCOAL PRODUCTS

被引:13
作者
KRENZELOK, EP
LUSH, RM
机构
[1] Pittsburgh Poison Center, Children's Hospital of Pittsburgh, Pittsburgh, PA
[2] Schools of Pharmacy and Medicine, University of Pittsburgh, Pittburgh, PA
关键词
AQUEOUS ACTIVATED CHARCOAL; ACTIVATED CHARCOAL;
D O I
10.1016/0735-6757(91)90176-K
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Commercial aqueous activated charcoal (AC) products may sit in emergency departments, pharmacies, and homes for prolonged periods resulting in the inability to resuspend the AC for patient administration. The potential risk to the patient from not receiving an adequate amount of AC, especially when AC may be the sole means of gastric decontamination, is obvious. To simulate this potential problem, samples of five different aqueous AC products (ActaChar, Actidose, InstaChar, LiquiChar, and SuperChar) were placed into storage for periods of 3 and 12 months. At the end of each study period, samples were agitated and the effluent and container residue were collected, oven-dried, and weighed. With the exception of Actidose, all products retained substantial amounts of AC in the container at both time intervals. These data stress the negative impact of dormant storage on the resuspendability of aqueous activated charcoal products. Furthermore, they suggest the importance of thorough container agitation and rinsing to insure that the patient receives sufficient AC. This is especially important when AC is the sole means of decontamination. © 1991.
引用
收藏
页码:144 / 146
页数:3
相关论文
共 10 条
[1]  
Neuvonen, Vartianen, Tokola, Comparison of activated charcoal and ipecac syrup in prevention of drug absorption, Eur J Clin Pharmacol, 24, pp. 557-562, (1983)
[2]  
Kulig, Bar-Or, Cantrill, Et al., Management of acutely poisoned patients without gastric emptying, Ann Emerg Med, 14, pp. 562-567, (1985)
[3]  
Tenenbein, Cohen, Sitar, Efficacy of ipecac-induced emesis, orogastric lavage, and activated charcoal for acute drug overdose, Ann Emerg Med, 16, pp. 838-841, (1987)
[4]  
Albertson, Derlet, Goulke, Et al., Superiority of activated charcoal alone compared with ipecac and activated charcoal in the treatment of acute toxic ingestions, Ann Emerg Med., 18, pp. 56-59, (1989)
[5]  
Burton, Bayer, Barron, Et al., Comparison of activated charcoal and gastric lavage in the prevention of aspirin absorption, J Emerg Med, 1, pp. 411-416, (1984)
[6]  
Park, Spector, Goldberg, Et al., Effect of the surface area of activated charcoal on theophylline clearance, J Clin Pharmacol, 24, pp. 289-292, (1984)
[7]  
Curd-Sneed, Parks, Bordelon, Et al., In vitro adsorption of sodium pentobarbital by SuperChar, USP and Darco G-60 activated charcoals, Clin Toxicol, 25, pp. 1-11, (1987)
[8]  
Krenzelok, Heller, Effectiveness of commercially available aqueous activated charcoal products, Ann Emerg Med, 16, pp. 1340-1343, (1987)
[9]  
Litovitz, Schmitz, Holm, 1988 Annual report of the American Association of Poison Control Centers National Data Collection System, Am J Emerg Med, 7, pp. 495-545, (1989)
[10]  
Grbcich, Lacouture, Kresel, Et al., Expired ipecac syrup efficacy, Pediatrics, 78, pp. 1085-1089, (1986)